Tyler Curiel, M.D., MPH

• Professional Background

  Education

  • 1983 - MPH - Epidemiology/Biostatistics - Harvard University
  • 1982 - MD - Medicine - Duke Medical School
  • 1977 - BS - Chemistry (summa cum laude, with highest honors, with honors in chemistry) - University of Georgia
  • Internship - Medicine - Yale Medical School & Yale-New Haven Hospital
  • Residency - Internal Medicine - Yale Medical School & Yale-New Haven Hospital
  • Postdoctoral Fellowship - Medical Oncology - University of Colorado Health Sciences Center
  • Postdoctoral Fellowship - Medicine - Harvard Medical School
  • Postdoctoral Fellowship - Infectious Disease - Harvard Medical School & Massachusetts General Hospital

  Appointments

  • 8/2006 - Professor of Medicine - UTHSCSA, Medicine, San Antonio

• Instruction & Training

  • 1/2018 - Present, UTHSCSA
  • 1/2018 - Present, UTHSCSA
  • 1/2018 - Present, UTHSCSA
  • 8/2013 - Present, Pre-Doctoral Student Supervision, UTHSCSA
  • 8/2013 - Present, Membership on Supervising Committee, UTHSCSA
  • 7/2013 - Present, Post-Doctoral Student Supervision, UTHSCSA
  • 8/2012 - Present, Pre-Doctoral Student Supervision, UTHSCSA
  • 7/2012 - Present, Membership on Supervising Committee, UTHSCSA
  • 1/2010 - Present, Refugee clinic
  • 1/2009 - Present, "Fronteras" Preceptor to first and second year UTHSCSA medical students, UTHSCSA
  • 1/2009 - Present, Clinical Preceptor for first and second year UTHSCSA medical students, UTHSCSA
  • 8/2008 - Present, Masters' Thesis Directed, UTHSCSA
  • 8/2008 - Present, Immunology, The University of Texas Health Science Center
  • 6/2008 - Present, Service-based learning for health care professionals - ELEC 5044 Healthy Choices for Kids, UTHSCSA
  • 1/2008 - Present, Core Concepts in Microbiology Immunology, The University of Texas Health Science Center
  • 1/2007 - Present, Pre-Doctoral Student Supervision, UTHSCSA

• Research & Grants

  Human immunology with an emphasis on understanding the immunopathologic basis of human diseases including cancer, infections and autoimmunity.

  Selected Publications

  Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila). 2014 Jan;7(1):169-78.

  Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18(6):573-83.

  Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods? Cell Cycle. 2013 Jan 1;12(1):20-5.

  Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.PLoS One. 2013;8(3):e58397.

  Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15;17(8):2250-9.

  Research profile

  Grants

  Federal

  Funding Agency
   

  Title
  NCI (PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration

  Status
  Active

  Period
  4/2017 - 3/2022

  Role
  Co-Investigator

  Grant Detail
  Council Meeting Date: 2017/01
  Meeting Date: 11/15/201

  Funding Agency
   

  Title
  NCI ?B7-H1 signals in ovarian cancer?

  Status
  Active

  Period
  9/2012 - 6/2017

  Role
  Principal Investigator

  Grant Detail
   

   

  Funding Agency
  Clayton Foundation

  Title
  ?Targeting novel tumor-intrinsic PD-L1/PD-1 pathways to optimize cancer immunotherapy?

  Status
  Active

  Period
  3/2018 - 12/2023

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  Tumor intrinsic B7-H1 in cancer pathogenesis

  Status
  Active

  Period
  4/2016 - 3/2022

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  NCI ?Regulation of ER-beta signaling in carcinogenesis?

  Status
  Active

  Period
  2/2017 - 1/2022

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
  Cancer Therapy and Research Center

  Title
  Role: Leader, Experimental and Developmental Therapeutics

  Status
  Active

  Period
  8/2015 - 7/2020

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  Immune effects of rapamycin in cancer prevention

  Status
  Active

  Period
  6/2014 - 5/2020

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  NIH ?San Antonio Claude D. Pepper Older Americans Independence Center

  Status
  Active

  Period
  6/2015 - 5/2020

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  CPRIT Gut integrin signals direct IL-18 in colon carcinogenesis

  Status
  Active

  Period
  5/2016 - 4/2019

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  ?Gut integrin signals direct IL-18 in colon carcinogenesis?

  Status
  Active

  Period
  5/2016 - 4/2019

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
  Ovarian Cancer Research Fund

  Title
  ?Rational design of effective multi-modal ovarian cancer immunotherapy?

  Status
  Active

  Period
  1/2014 - 12/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  ?Phase I trial of anti-PD-L1 antibody in selected solid tumors?

  Status
  Active

  Period
  11/2012 - 11/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  CDMRP ?Novel B7-H1 immune co-signaling effects on estrogens in lupus?

  Status
  Active

  Period
  7/2014 - 9/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  CDMRP ?Testing ER-beta agonist synergy with B7-H1 and mTOR inhibitors as novel and effective treatments for ovarian cancer?

  Status
  Active

  Period
  5/2015 - 7/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  CDMRP ?Novel Listeria vectors secreting gut flora-altering agents to prevent colon cancer and treat colitis?

  Status
  Active

  Period
  5/2015 - 7/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  Rational design of effective multi-modal ovarian cancer immunotherapy Ovarian Cancer Research Fund

  Status
  Active

  Period
  1/2014 - 1/2018

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  Development of very promising fully human therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers?

  Status
  Active

  Period
  11/2013 - 8/2017

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
   

  Title
  Improving efficacy of BCG for bladder cancer

  Status
  Active

  Period
  7/2013 - 6/2017

  Role
  Co-Investigator

  Grant Detail
   

• Publications

  Journal Article

  Curiel TJ. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model Experimental Gerontology 2018 Jan;105:146-154.

  Ellen Kraig, Leslie A. Linehan, Hanyu Liang, Terry Q. Romo,
  Qianqian Liu, Yubo Wu, Adriana D. Benavides, Tyler J. Curiel,
  Martin A. Javors, Nicolas Musi, Laura Chiodo, Wouter Koek,
  Jonathan A.L. Gelfond, Dean L. Kellogg. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects Experimental Gerontology 2018 Jan;105:53-69.

  Zhang X., Huai-Chin Chiang, Yao Wang, Chi Zhang, Sabrina Smith, Xiayan Zhao, Sreejith Nair, Joel Michalek, Ismail Jatoi, Meeghan Lautner, Boyce Oliver, Howard Wang, Anna Petit, M Teresa Soler Monso, Joan Brunet, Francesca Mateo, Miguel Pujana, Elizabeth Poggi, Krysta Chaldekas, Claudine Isaacs, Beth Peshkin, Oscar Ochoa, Frederic Che'din, Constantine Theoharis, Lu-Zhe Sun, Tyler Curiel, Richard Elledge, Victor Jin, Yanfen Hu, and Rong Li. Attenuation of RNA Polymerase II Pausing Mitigates BRCA1-Associated R-loop Accumulation and Tumorigenesis Nat Commun 2017 Jun;26(8).

  Curiel TJ. Tumor cell-intrinsic PD-L1: a novel metabolic balancing act with clinical potential Autophagy 2017 Jan;13(5):987-988.

  Curiel TJ. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target Clinical Cancer Research 2017 Jan;23:441-453.

  Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts Clinical & Experimental Immunology 2017 Jan;187:53-63.

  Curiel TJ. Biphasic rapamycin effects in lymphoma and carcinoma treatment Cancer Research 2017 Jan;77:520-531.

  Curiel TJ. Acquired resistance to BRAF inhibitors restores immunosuppressive myeloid cells that impair immunotherapy against autochthonous mouse melanoma Cancer Research 2017 Jan;77:1599-1610.

  Curiel TJ. Characterization of tumor-driven Th17-to-Treg cell transdifferentiation Nature Communications 2017 Jan;8.

  Curiel TJ. Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice Journal of Biological Chemistry 2017 Jan;293(8):2841-2849.

  Curiel TJ. Tumor cell-independent estrogen signaling drives progression through mobilization of myeloid-derived suppressor cells Cancer Discovery 2017 Jan;7:72-85.

  Curiel TJ. Tumor intrinsic PD-L1 promotes tumor initiating cell generation and functions Signal Transduction and Targeted Therapy 2016 Jan;.

  Curiel TJ. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma Cancer Research 2016 Jan;76:6964-6974.

  Curiel TJ. Immune stimulatory effects of rapamycin are mediated by stimulation of antitumor γδ T cells Cancer Research 2016 Jan;76:5970-5982.

  Curiel TJ. Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer Oncotarget 2016 Jan;7:42585-42597.

  Curiel TJ. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-PD-L1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer Journal of Clinical Oncology 2016 Jan;34:3119-3125.

  Hurez V, Dao V, Liu A, Pandeswara S, Gelfond J, Sun L, Bergman M, Orihuela J, Galvan V, Padron A, Drerup J, Liu Y, Hasty P, Sharp ZD, Curiel TJ. Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid and innate lymphoid cells and gut flora and prolongs life of immune deficient mice. (In Press) Aging Cell 2015 Jan;14(6):945-956.

  Curiel TJ. Immunotherapy for Ovarian Cancer Current Treatment Options in Oncology 2015 Jan;.

  Curiel TJ. Sequential Intravesical Mitomycin plus Bacillus Calmette-Guerin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial Clinical Cancer Research 2015 Jan;21:303-311.

  Curiel TJ. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 2015 Jan;14:497-510.

  Curiel TJ. Host miR-155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism Cancer Research 2015 Jan;75:519-531.

  Curiel TJ. Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage Cancer Prevention Research 2015 Jan;8:400-409.

  Messer JC, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis Urology 2014 Apr;83:863-867.

  Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. PMID 15313886 Cancer Res 2004 Aug;64(16):5535-5538.